Calamos Advisors LLC Purchases New Holdings in Vera Therapeutics, Inc. $VERA

Calamos Advisors LLC bought a new position in Vera Therapeutics, Inc. (NASDAQ:VERA) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 13,146 shares of the company’s stock, valued at approximately $529,000.

A number of other institutional investors have also recently bought and sold shares of VERA. GAMMA Investing LLC boosted its holdings in shares of Vera Therapeutics by 50.5% in the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after acquiring an additional 236 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Vera Therapeutics in the 4th quarter worth $46,000. Quantbot Technologies LP acquired a new stake in shares of Vera Therapeutics during the second quarter worth $51,000. Aster Capital Management DIFC Ltd bought a new stake in Vera Therapeutics in the fourth quarter valued at about $71,000. Finally, Tower Research Capital LLC TRC increased its holdings in Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after purchasing an additional 2,757 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Needham & Company LLC set a $125.00 price objective on shares of Vera Therapeutics in a report on Wednesday, July 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. The Goldman Sachs Group reiterated a “buy” rating and set a $90.00 price objective on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Wedbush lifted their price target on shares of Vera Therapeutics from $35.00 to $43.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Finally, Evercore set a $91.00 price target on shares of Vera Therapeutics in a report on Friday, May 15th. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $84.58.

Vera Therapeutics Stock Down 1.6%

Shares of NASDAQ VERA opened at $38.50 on Friday. The company’s 50 day moving average price is $37.14 and its 200-day moving average price is $40.64. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. Vera Therapeutics, Inc. has a 52-week low of $19.07 and a 52-week high of $56.05. The company has a market capitalization of $2.76 billion, a P/E ratio of -6.95 and a beta of 0.92.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter in the prior year, the company earned ($0.81) EPS. Equities analysts forecast that Vera Therapeutics, Inc. will post -6.37 earnings per share for the current year.

Insider Activity

In related news, CEO Marshall Fordyce sold 46,250 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total value of $1,956,375.00. Following the sale, the chief executive officer directly owned 151,994 shares of the company’s stock, valued at $6,429,346.20. This represents a 23.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 83,250 shares of company stock valued at $3,337,770 in the last 90 days. 15.90% of the stock is currently owned by insiders.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.